The analysts at Wall Street are expected the stocks of HOLX to announce revenue of around $1.38 billion for this quarter. According to reports, five of the analysts working at the firm have estimated the earnings of this company, with the estimates moving from $1.32 billion to $1.40 billion. The company did report sales of around $850.50 million for the same quarter just the previous year. And this indicates an impressive annual growth rate of around 62.3% on the stocks of the company. The company will be posting its next earnings results on the 3rd of February.
The Quarterly Earnings Of HOLX
The company did update its last quarterly earnings results on the 4th of November. This provider of medical equipment had reported an EPS of $2.07 for this quarter, which was considerably more than the consensus estimate of $1.22. The net margin of the company was 29.53%, with a return on its equity set at 45.24%. The revenue for the company was $1.35 billion, which was also more than the analyst estimate of $1.11 billion.
There have been quite a few firms that have researched the stocks of HOLX. Smith Barney Citigroup has already increased the target price on the company from $85 to $90 in one of their research notes on the 5th of November. Needham & Company LLC has, on the other hand, lowered the ratings of the company from ‘buy’ to ‘hold’ in yet another research note that was published on the 20th of November.
Argus has reported an increase in their price target from $85 to $100 in one of their research articles. Jefferies Financial Group, too, joined in on the fun with a price objective of $98 on the stocks of the company. In the end, Raymond James came in with a price target of $86, while giving the company a rating of ‘outperform’ in one of their research notes that was published on the 5th of November.
One of the investment analysts working on the firm has already given it a rating of sell. Five of them have given it a rating of ‘hold’, while ten of them have issued it a rating of ‘buy’. The rating for HOLX is ‘Buy’, whereas the price target is $79.12.